The global pandemic has ushered in extraordinary roadblocks for the pharmaceutical industry. Practitioners and litigants are battling with unforeseen hurdles as they navigate FDA approval schedules, filing deadlines and launch dates, and practicing law in the virtual courtroom.

You asked, we listened.

In response, we are excited to introduce ACI’s Paragraph IV on Virtual Trial: COVID–19 Edition, a new virtual conference designed to guide you through the many procedural dilemmas that ANDA litigators are experiencing as a result of the novel coronavirus. This special one-day event will address and provide solutions to coronavirus-related disruptions to Hatch-Waxman litigation.

MEET THE CO-CHAIRS
Guy Donatiello

Guy Donatiello

Senior Vice President, Intellectual Property
Endo Pharmaceuticals

Josephine Liu

Josephine Liu

Vice President of IP, North America
Sandoz

Fireside Chat with The Federal Circuit
Hon. Kathleen M. O'Malley

Hon. Kathleen M. O’Malley

United States Circuit Judge

Interviewed By:

Hon. Mary Pat Thynge

Hon. Mary Pat Thynge

Chief Magistrate Judge
United States Federal District Court, District of Delaware

Spotlight on the USPTO
Hon. Jacqueline D. Wright Bonilla

Hon. Jacqueline D. Wright Bonilla

Deputy Chief Administrative Patent Judge
Patent Trial and Appeal Board
U.S. Patent and Trademark Office

Virtual Courtroom: Navigating Paragraph IV Litigating from Home
Virtual Discovery
Ryan M. Daniel

Ryan M. Daniel

Chief Patent Counsel, Region North America
Fresenius Kabi USA, LLC

Impact to Motion Practice
Stephanie L. Donahue

Stephanie L. Donahue

Senior Director, Patent Litigation
Sanofi